Retirement Planning Group LLC Makes New Investment in Gilead Sciences, Inc. $GILD

Retirement Planning Group LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, Holdings Channel reports. The firm bought 5,226 shares of the biopharmaceutical company’s stock, valued at approximately $641,000.

Other institutional investors have also recently bought and sold shares of the company. Corundum Trust Company INC acquired a new stake in Gilead Sciences during the 3rd quarter worth $26,000. Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the 4th quarter worth $28,000. Financial Consulate Inc. grew its holdings in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares during the period. North Star Investment Management Corp. grew its holdings in Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 86 shares during the period. Finally, MTM Investment Management LLC grew its holdings in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $134.06 on Friday. The firm has a market cap of $166.40 billion, a PE ratio of 19.80, a PEG ratio of 1.80 and a beta of 0.31. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1-year low of $95.29 and a 1-year high of $157.29. The company has a fifty day moving average price of $139.59 and a 200 day moving average price of $132.87.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts predict that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is presently 48.45%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q1 results beat estimates — Gilead reported $2.03 EPS vs. a $1.89 consensus and revenue of $6.96B vs. ~$6.91B, showing underlying quarter strength. Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 sales forecast, indicating revenue strength despite other headwinds. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
• Neutral Sentiment: Full‑year revenue guidance was issued at roughly $30.0–30.4B, near analyst consensus — so sales expectations are roughly intact even as profit guidance shifted. Gilead Press Release / Slide Deck
• Neutral Sentiment: Shareholders approved the board and executive pay plans at the 2026 meeting — governance items cleared without disruption. Gilead Shareholders Back Board, Pay Plans at 2026 Meeting
• Negative Sentiment: Company withdrew prior profit guidance and now expects an adjusted FY2026 loss of $1.05 to $0.65 per share (versus prior ~$8.45–8.85 outlook and analyst expectations near $8.65), a dramatic revision that hits valuation and investor confidence. Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
• Negative Sentiment: Management attributes the profit swing to acquisition‑related charges and financing costs tied to recent deals — these one‑time and financing items meaningfully depress reported earnings for the year. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Analyst Upgrades and Downgrades

A number of research firms have commented on GILD. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Jefferies Financial Group began coverage on shares of Gilead Sciences in a report on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price for the company. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 14th. Morgan Stanley lifted their target price on shares of Gilead Sciences from $171.00 to $175.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Finally, Cantor Fitzgerald lowered their target price on shares of Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 10th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $157.35.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. This represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider directly owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 63,000 shares of company stock valued at $9,238,250. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.